In many ways, these findings reflect similar work done in breast cancer, where Slyper et al. found that TCF7L1 knockdown reduced cancer cell growth and that patients with high levels of TCF7L1 expression had poorer clinical outcomes27. The gene discussed is TCF7L1; the disease is breast carcinoma.